Short Interest in FocalTherics (NASDAQ:FOCL) Increases By 140.7%

FocalTherics (NASDAQ:FOCL) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 134,939 shares, an increase of 140.7% from the May 31st total of 56,059 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 40,322 shares, the days-to-cover ratio is currently 3.3 days.

Insider Activity

In other FocalTherics news, Director Joshua Levine acquired 10,000 shares of the company’s stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $4.22 per share, with a total value of $42,200.00. Following the completion of the acquisition, the director directly owned 35,000 shares in the company, valued at $147,700. This trade represents a 40.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On FocalTherics

A number of large investors have recently added to or reduced their stakes in FOCL. Financial Planning Navigators CORP purchased a new stake in FocalTherics during the fourth quarter valued at about $33,000. Leonteq Securities AG purchased a new stake in FocalTherics during the 4th quarter valued at about $313,000. Kovack Advisors Inc. bought a new position in shares of FocalTherics in the fourth quarter worth approximately $53,000. Rock Springs Capital Management LP grew its holdings in FocalTherics by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Finally, Flax Pond Capital LLC bought a new stake in shares of FocalTherics in the fourth quarter worth about $2,623,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

FocalTherics Price Performance

Shares of FocalTherics stock traded up $0.05 during trading on Monday, hitting $5.15. 37,969 shares of the stock traded hands, compared to its average volume of 53,063. The firm has a market capitalization of $193.02 million and a PE ratio of -6.36. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. FocalTherics has a 52 week low of $1.21 and a 52 week high of $5.24.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%.The firm had revenue of $20.48 million during the quarter, compared to analysts’ expectations of $19.46 million. Sell-side analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on FOCL. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, FocalTherics currently has an average rating of “Hold” and a consensus target price of $6.00.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.